36 related articles for article (PubMed ID: 23933045)
21. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
24. Inherent efficacies of pyrazole-based derivatives for cancer therapy: the interface between experiment and
Dube ZF; Soremekun OS; Ntombela T; Alahmdi MI; Abo-Dya NE; Sidhom PA; Shawky AM; Shibl MF; Ibrahim MA; Soliman ME
Future Med Chem; 2023 Sep; 15(18):1719-1738. PubMed ID: 37772542
[TBL] [Abstract][Full Text] [Related]
25. Pyrazole scaffold: a remarkable tool in the development of anticancer agents.
Kumar H; Saini D; Jain S; Jain N
Eur J Med Chem; 2013; 70():248-58. PubMed ID: 24161702
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.
Sun J; Lv XH; Qiu HY; Wang YT; Du QR; Li DD; Yang YH; Zhu HL
Eur J Med Chem; 2013 Oct; 68():1-9. PubMed ID: 23933045
[TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
28. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
29. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.
Liu Y; Fu L; Wu J; Liu M; Wang G; Liu B; Zhang L
Eur J Med Chem; 2022 Feb; 229():114056. PubMed ID: 34942431
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.
El-Gamal MI; Zaraei SO; Madkour MM; Anbar HS
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011562
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
